CN101440032B - Gemfibrozil polycrystalline type and preparation thereof - Google Patents
Gemfibrozil polycrystalline type and preparation thereof Download PDFInfo
- Publication number
- CN101440032B CN101440032B CN2008101620237A CN200810162023A CN101440032B CN 101440032 B CN101440032 B CN 101440032B CN 2008101620237 A CN2008101620237 A CN 2008101620237A CN 200810162023 A CN200810162023 A CN 200810162023A CN 101440032 B CN101440032 B CN 101440032B
- Authority
- CN
- China
- Prior art keywords
- gemfibrozil
- degrees
- crystal form
- preparation
- toluene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
The invention relates to a Gemfibrozil crystal form II and a preparation method thereof. Gemfibrozil is dissolved through with certain amount of toluene and is crystallized, filtered and dried to form a new Gemfibrozil crystal form. The X-ray diffraction pattern of the crystal form shows character diffraction peaks at 2theta(degree,+/-0.2)5.85 degrees, 8.06 degrees, 8.51 degrees, 11.49 degrees, 11.79 degrees, 12.66 degrees, 12.86 degrees, 13.43 degrees, 13.78 degrees, 16.24 degrees, 16.59 degrees, 17.12 degrees, 19.00 degrees, 20.86 degrees, 21.88 degrees, 23.23 degrees, and 24.14 degrees andhas the advantages that the crystal form has good stability and no static electricity, is convenient to produce, transport and store, and can meet all requirements as a preparation material and the like. The Gemfibrozil crystal form II can be kept unchanged for two years under the condition of normal temperature, does not reduce the content of medicine and fully meets the requirement of the medicine.
Description
Technical field
The invention belongs to the pharmaceutical chemistry technical field.Relate to the polymorphous preparation method of gemfibrozil, be specifically related to gemfibrozil crystal form II and preparation method thereof.
Background technology
Gemfibrozil (Gemfibrozil) chemistry is called 2,2-dimethyl--5-(2,5-xylyl oxygen base)-valeric acid, English 5-by name (2,5-dimethylphenoxy)-2,2-dimethylpentanoic acid, structural formula is following:
Gemfibrozil is nineteen eighty-two at the atorvastatin of U.S.'s listing, and it has overcome in the past that the hypolipidemic clofibrate has kept its useful effect to the serious toxic side effect of liver; Be used to prevent arteriosclerosis, help to reduce the sickness rate of myocardial infarction, oral back gastrointestinal absorption is good; Can take for a long time, therefore receive hyperlipidemia patient's welcome. because this medicine is safe and reliable, receive the approval of The World Health Organization (WHO) and U.S. pharmaceutical control and administration department (FDA); Enrolled USP, become official drug.
The preparation method of gemfibrozil has bibliographical information, and patent EP0462066 has reported the unformed preparation method of a kind of gemfibrozil, but does not still have the report of other crystal formation of gemfibrozil up to now.Unformed gemfibrozil poor stability very easily makes the transition under normal preservation condition, need be dispersed in the superpolymer medium and preserve.
Chinese patent 200710008478.4 discloses a kind of gemfibrozil powder of submicron order, adopts reaction-crystallization method, obtains the powder of 500-5um, but poor stability.
Summary of the invention
The present invention is directed to the unformed poor stability of gemfibrozil that prior art exists, preserve the problem of difficulty, polymorphous preparation method of gemfibrozil is provided, obtained the gemfibrozil crystal form II, have good stability, no static, be convenient to produce, transport and store.
The present invention provides the gemfibrozil crystal form II.The X ray diffracting spectrum of this crystal formation is 5.85 ° of 2 θ (°, ± 0.2), 8.06 °, 8.51 °, 11.49 °; 11.79 °, 12.66 °, 12.86 °, 13.43 °, 13.78 °; 16.24 °, 16.59 °, 17.12 °, 19.00 °, 20.86 °; 21.88 °, 23.23 °, places such as 24.14 ° demonstrate characteristic diffraction peak; In differential thermal analysis curve, locate, show endotherm(ic)peak at 59.3 ℃.
The present invention provides polymorphous preparation method of gemfibrozil, be with gemfibrozil with a certain amount of toluene dissolving, crystallization, filtration, drying, form a kind of new gemfibrozil crystal form II.Its preparation process is following:
(a) be 0.5～2 by the weight of gemfibrozil and the volume ratio of toluene solvant, in the toluene that gemfibrozil is joined, 50 ℃ of reflux, stirring and dissolving forms gemfibrozil solution;
(b) with above-mentioned solution cooling crystallization;
(c) filtering separation obtains solid, in 8 hours dryings of 40 ℃ of following vacuum dryings, gets the gemfibrozil crystal form II.
The present invention provides polymorphous preparation method of gemfibrozil, and technology is simple, and the gemfibrozil crystal form II of acquisition has good stability, no static, is convenient to produce, transports and stores, and can satisfy the advantages such as all requirements as preparation raw material.Test shows that the present invention prepares the gemfibrozil of crystal formation, can preserve that crystal formation does not change basically more than 2 years at normal temperature condition, and medicament contg does not reduce, and meets the requirement of medicine fully.
Description of drawings
Accompanying drawing 1 is the X-ray powder diffraction collection of illustrative plates (XRD) of gemfibrozil crystal form II;
Accompanying drawing 2 is differential thermal analysis curves (DS) of gemfibrozil crystal form II;
Embodiment
Embodiment 1: the preparation of gemfibrozil crystal form II
The 10g gemfibrozil is joined in the 5mL toluene, and heating (about 50 ℃) refluxes, stirs until dissolving fully, and cooling crystallization filters, 40 ℃ of following vacuum dryings 8 hours, the gemfibrozil crystal form II.
Embodiment 2: the preparation of gemfibrozil crystal form II
The 10g gemfibrozil is joined in the 10mL toluene, and heating (about 50 ℃) refluxes, stirs until dissolving fully, and cooling crystallization filters, 40 ℃ of following vacuum dryings 8 hours, the gemfibrozil crystal form II.
Embodiment 3: the preparation of gemfibrozil crystal form II
The 10g gemfibrozil is joined in the 20mL toluene, and heating (about 50 ℃) refluxes, stirs until dissolving fully, and cooling crystallization filters, 40 ℃ of following vacuum dryings 8 hours, the gemfibrozil crystal form II.
The gemfibrozil crystal form II X-ray powder diffraction collection of illustrative plates (XRD) of the foregoing description 1-3 is seen Fig. 1, and the X ray diffracting spectrum of crystal formation is 5.85 ° of 2 θ (°, ± 0.2), 8.06 °, 8.51 °; 11.49 °, 11.79 °, 12.66 °, 12.86 °, 13.43 °; 13.78 °, 16.24 °, 16.59 °, 17.12 °, 19.00 °; 20.86 °, 21.88 °, 23.23 °, 24.14 °, demonstrate characteristic diffraction peak.In differential thermal analysis curve, locate for 59.3 ℃, show endotherm(ic)peak.See Fig. 2.
Claims (2)
1. gemfibrozil crystal form II, it is characterized in that: said gemfibrozil crystal form II has X-ray powder diffraction collection of illustrative plates as shown in Figure 1; In differential thermal analysis curve, locate, show endotherm(ic)peak at 59.3 ℃.
2. the preparation method of the said gemfibrozil crystal form II of claim 1, step is following:
(a) ratio by the weight g of gemfibrozil and the volume ml of toluene solvant is 0.5～2, gemfibrozil is joined in the toluene, and 50 ℃ of reflux, stirring and dissolving forms gemfibrozil solution;
(b) with above-mentioned solution cooling crystallization;
(c) filtering separation obtains solid, 40 ℃ of following vacuum-dryings 8 hours, gets the gemfibrozil crystal form II.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008101620237A CN101440032B (en) | 2008-11-13 | 2008-11-13 | Gemfibrozil polycrystalline type and preparation thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008101620237A CN101440032B (en) | 2008-11-13 | 2008-11-13 | Gemfibrozil polycrystalline type and preparation thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101440032A CN101440032A (en) | 2009-05-27 |
| CN101440032B true CN101440032B (en) | 2012-05-23 |
Family
ID=40724663
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008101620237A Expired - Fee Related CN101440032B (en) | 2008-11-13 | 2008-11-13 | Gemfibrozil polycrystalline type and preparation thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101440032B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN86108472A (en) * | 1985-12-09 | 1987-07-22 | 沃纳·兰伯特公司 | 5-(2, the 5-dimethyl phenoxy)-2,2-dimethyl valeric acid preparation method's improvement |
| US5492700A (en) * | 1991-11-26 | 1996-02-20 | Warner-Lambert Company | Process and composition for the development of controlled release gemfibrozil dosage form |
-
2008
- 2008-11-13 CN CN2008101620237A patent/CN101440032B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN86108472A (en) * | 1985-12-09 | 1987-07-22 | 沃纳·兰伯特公司 | 5-(2, the 5-dimethyl phenoxy)-2,2-dimethyl valeric acid preparation method's improvement |
| US5492700A (en) * | 1991-11-26 | 1996-02-20 | Warner-Lambert Company | Process and composition for the development of controlled release gemfibrozil dosage form |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101440032A (en) | 2009-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101318948B (en) | Lubiprostone1 crystal, preparation method and uses thereof | |
| CN101863872B (en) | Method for extracting PiPerlonguminine and drug combination comprising same | |
| CN103304476A (en) | Preparation method of ibuprofen-nicotinamide eutectic crystals | |
| CN101440032B (en) | Gemfibrozil polycrystalline type and preparation thereof | |
| CN101028316B (en) | Use of Starfruit root in preparing medicine for treating diabetes medicine | |
| CN101768105A (en) | Crystal form of butyric acid clevidipine | |
| CN102260244A (en) | Stable rabeprazole sodium compound | |
| CN101555202B (en) | Gemfibrozil polymorphism and preparation method thereof | |
| CN102531878A (en) | Novel crystal form of sodium valproate, and preparation method and application thereof | |
| CN103142474B (en) | With the composition and method of making the same that high purity bilobalide B is active component | |
| CN105646520A (en) | Stable Halaven compound | |
| CN106543180B (en) | Benzoic acid Li Gelieting crystal formations and preparation method thereof | |
| CN103755692B (en) | A kind of compound and preparation method thereof, purposes, pharmaceutical composition and preparation | |
| CN1594355B (en) | Cyclovirobuxinum D crystal, its mono-methanol crystal, and preparation and use thereof | |
| CN101190889B (en) | Method for preparing ibuprofen arginine | |
| CN109160901A (en) | A kind of metronidazole pharmaceutical co-crystals and preparation method thereof | |
| WO2014044028A1 (en) | Anti lung cancer drug made of oleum cassiae and major constituent cinnamaldehyde thereof and use thereof | |
| CN101564410B (en) | Method for extracting anti-tumor active substance from common cephalanoplos herb and common cephalanoplos herb anti-tumor medicament | |
| CN102397264A (en) | Method for preparing sinomenine hydrochloride sustained-release tablet | |
| CN108752362B (en) | Forsythiagenin methanol compound, crystal form A and preparation method thereof | |
| CN103059085B (en) | A kind of Anti-cancer medicament intermediate and preparation method thereof | |
| CN112480047A (en) | Compound with blood sugar reducing and lipid regulating effects, preparation and application thereof | |
| CN103142473B (en) | A kind of composition and method of making the same containing high purity bilobalide B | |
| CN103781774A (en) | New crystalline form | |
| CN103848831B (en) | Doxofylline compound and pharmaceutical composition thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120523 Termination date: 20151113 |
|
| EXPY | Termination of patent right or utility model |